Persistent Systems launches Nvidia-backed AI solution for generative molecules, virtual screening; stock reacts

Persistent Systems Ltd announced on Tuesday that it is collaborating with Nvidia to accelerate AI-powered solutions designed for the Healthcare and Life Sciences (HLS) industries. 

At 1:11 pm, Persistent Systems shares were trading 2.48% lower at Rs 4528.90 per share on the BSE, down from their previous close of Rs 4,643.85. The counter has faced selling pressure recently, declining nearly 6% over the last five trading sessions.

According to a stock exchange filing, the digital engineering leader has launched a Generative Molecules and Virtual Screening (GenMolVS) solution that leverages the NVIDIA BioNeMo platform.

The new solution aims to transform early-stage drug discovery by moving from Al experimentation to real-world production deployments in mission-critical environments, the company said.

The collaboration allows life sciences enterprises to "model and reason real-world biological and chemical behavior before it is realized in real-world wet laboratory environments," it said.

Persistent Systems plans to further enhance the GenMolVS solution using Nvidia NeMo open models. To support these production-grade applications, the company will utilise NVIDIA accelerated computes, servers, and NIM microservices. 

“Together, these capabilities will expedite cost-effective development of applications with costeffective scaling options, with highly accurate AI outputs embedded directly into enterprise workflows,” the company said.

John Fanelli, Vice President of Enterprise Software at NVIDIA, noted that the industry is rapidly moving toward AI-driven computational research. “By leveraging the fullstack NVIDIA AI platform, Persistent is empowering biopharma companies with productiongrade agentic systems for molecular simulation and virtual screening,” Fanelli said.